Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites. Date range. Start Date. End Date. Corporate Vaccines Medicines Sustainability Consumer healthcare Research and development. Select date …
Press releases | GSK US
WEBUS FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit. Jemperli approval now includes MMRp/MSS tumors, which represent majority of endometrial cancer cases.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
GSK's experimental drug shows promise in reducing severe …
WEBMay 21 (Reuters) - GSK's (GSK.L) experimental drug met its primary goal of reducing asthma attacks in a late-stage trial, marking a bright spot for a treatment that the British drugmaker expects to...
GSK plc (GSK) Latest Stock News & Headlines - Yahoo Finance
WEBGet the latest GSK plc (GSK) stock news and headlines to help you in your trading and investing decisions.
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
WEBLONDON, Feb 15 (Reuters) - GSK (GSK.L) said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory...
GSK lifts annual forecasts again, powered by strong vaccine launch
WEBNov 1 (Reuters) - GSK (GSK.L) raised its full-year profit and sales forecasts for a second time on Wednesday, following the strong launch of its respiratory syncytial virus (RSV) vaccine in the...
GSK posts blowout RSV vaccine sales, raises outlook - CNBC
WEBJan 31, 2024 · GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. The shot targeting the severe and in some …
GSK to acquire clinical-stage biopharmaceutical company …
WEBMay 31, 2022 · GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones. Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS TM technology. Supports development of a strong portfolio of innovative vaccines …
GlaxoSmithKline (GSK) Gains FDA Clearance for First HIV Prevention ...
WEBDec 21, 2021 · GlaxoSmithKline Plc received U.S. clearance for the first long-acting injection for the prevention of HIV, a significant development for the company as it prepares to split in two next year.